Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells

  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • Trincado Alonso, Juan Luis, 1987-|||0000-0001-5363-3774
  • Vinyoles, Meritxell|||0000-0003-1906-4701
  • Closa, Adria|||0000-0002-9302-337X
  • Martínez Moreno, Alba|||0000-0001-7514-260X
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Molina, Oscar|||0000-0001-7585-4519
  • Rodríguez-Cortez, Virginia Carolina|||0000-0002-0853-247X
  • Ximeno-Parpal, Pau|||0000-0003-1814-9607
  • Fernández Fuentes, Narcís|||0000-0002-6421-1080
  • Petazzi, Paolo|||0000-0002-1036-2895
  • Beneyto Calabuig, Sergi|||0000-0003-3773-8239
  • Velten, Lars
  • Romecín, Paola Alejandra|||0000-0001-6890-5883
  • Casquero, Raquel
  • Abollo-Jiménez, Fernando
  • de la Guardia, Rafael D.
  • Lorden, Patricia
  • Bataller, Alex|||0000-0002-6085-2745
  • Lapillonne, Hélène|||0000-0002-6900-8313
  • Stam, Ronald W.
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Torrebadell, Montserrat
  • Fuster, José Luis|||0000-0002-4881-9440
  • Bueno, Clara|||0000-0003-1442-6216
  • Sarry, Jean Emmanuel
  • Eyras, Eduardo|||0000-0003-0793-6218
  • Heyn, Holger|||0000-0002-3276-1889
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Relapse remains a major challenge in the clinical management of acute myeloid leukemia (AML) and is driven by rare therapy-resistant leukemia stem cells (LSCs) that reside in specific bone marrow niches. Hypoxia signaling maintains cells in a quiescent and metabolically relaxed state, desensitizing them to chemotherapy. This suggests the hypothesis that hypoxia contributes to the chemoresistance of AML-LSCs and may represent a therapeutic target to sensitize AML-LSCs to chemotherapy. Here, we identify HIF and HIF specific AML subgroups (inv(16)/t(8;21) and MLLr, respectively) and provide a comprehensive single-cell expression atlas of 119,000 AML cells and AML-LSCs in paired diagnostic-relapse samples from these molecular subgroups. The HIF/hypoxia pathway signature is attenuated in AML-LSCs compared with more differentiated AML cells but is more expressed than in healthy hematopoietic cells. Importantly, chemical inhibition of HIF cooperates with standard-of-care chemotherapy to impair AML growth and to substantially eliminate AML-LSCs in vitro and in vivo. These findings support the HIF pathway in the stem cell-driven drug resistance of AML and unravel avenues for combinatorial targeted and chemotherapy-based approaches to specifically eliminate AML-LSCs.